FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308399087> ?p ?o ?g. }

• W4308399087 abstract "<h3>Background</h3> Neoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable MEL with durable relapse-free benefit, and increased circulating activated CD8+ T cells.^1,2 Vidutolimod (vidu) comprises a CpG-A oligodeoxynucleotide packaged within a virus-like particle (VLP) and is designed to activate tumor-associated plasmacytoid dendritic cells (pDC) via TLR9, inducing an IFN-rich tumor microenvironment and anti-tumor CD8+ T cell responses. Vidu/anti-PD-1 resulted in durable tumor responses in PD-1 refractory MEL.³ This phase II study evaluated the pathological, clinical and immunological activities of neoadjuvant vidu/nivo in high-risk stage III B/C/D resectable MEL. <h3>Methods</h3> Vidu/nivo was administered over 7 weeks (vidu 10mg IT Q1W x7, nivo 240mg Q2W x3) pre-surgery. Post-surgery, vidu/nivo (vidu SC 5mg, nivo 480mg Q4W) was continued for 48 weeks. Primary endpoints included MPR rate, and incidence of DLT. Secondary endpoints were radiographic response, relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS). Pathological response assessment was performed to evaluate % residual volume of tumor (RVT) per consensus criteria^4-6 by 3 blinded dermatopathologists: 0% (pCR); 0%50% (pNR). Radiographic response assessed using RECIST v1.1. Serial blood, tumor and stool were collected for correlative analyses. <h3>Results</h3> 31 pts were enrolled, of whom 30 evaluable for per-protocol (PP) analyses as 1 pt progressed pre-surgery. No DLTs were observed. 8 Gr3 TRAE, including hypertension (7/8) and colitis (1/8) were observed; no delays in surgery occurred. ORR by BICR was 45% (all) and 47% (PP). In PP population, MPR was observed in 57% (17/30) including 47% pCR (14/30) and 10% pMR (3/30). With median follow-up of 26.5 months, median RFS was not reached (table 1). Post-treatment, MPR was associated with increased CD8+ tumor infiltrating lymphocytes (p<0.0001), and peripheral immune activation and pDC activation by multiparameter flow cytometry (p < 0.001). Spatial investigation of immune cell infiltrates by mIHC revealed significantly immune cell infiltrates (p<0.05) and higher pDC (p=0.053) within tumor (but not stroma) of MPRs post-treatment (figure 1a,b). Deconvoluted RNAseq confirmed these findings compared to a control cohort of PD-1 treated MEL. <h3>Conclusions</h3> Neoadjuvant vidu/nivo has minimal tox and demonstrated promising activity with 47% pCR rate and 57% MPR rate. MPR was associated with improved 1-/2- year RFS (94%/88%), and 1-/2- year DMFS (94%/94%) and 2-year OS (100%). MPR is associated with pDC and immune infiltrate (figure 1c). Further evaluation of this combination is ongoing in an ongoing randomized phase II trial (EA6194, NCT04708418). <h3>Acknowledgements</h3> We thank and Checkmate Pharmaceuticals for funding and vidutolimod. This research was supported in part by the University of Pittsburgh Center for Research Computing through the resources provided. Specifically, this work used the HTC cluster, which is supported by NIH award number S10OD028483. This research was supported by the Melanoma Research Foundation Breakthrough Consortium (MRFBC) Award (Davar, Stein); NIH R01 CA257265 (Zarour, Davar); and NIH P50 CA254865 (Zarour). <h3>Trial Registration</h3> Clinical trial information: NCT03618641. <h3>References</h3> Amaria RN, Reddy SM, Tawbi HA, <i>et al</i>. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nat Med</i>. 2018 Nov;<b>24</b>(11):1649–1654. Huang AC, Orlowski RJ, Xu X, <i>et al</i>. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nat Med</i>. 2019 Mar;<b>25</b>(3):454–461. doi: 10.1038/s41591-019-0357-y. Ribas A, Medina T, Kirkwood JM, <i>et al</i>. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discov</i>. 2021 Dec 1;<b>11</b>(12):2998–3007. doi: 10.1158/2159-8290.CD-21-0425. Tetzlaff MT, Messina JL, Stein JE, <i>et al</i>. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Ann Oncol</i>. 2018 Aug 1;<b>29</b>(8):1861–1868. Cottrell TR, Thompson ED, Forde PM, <i>et al</i>. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <i>Ann Oncol</i>. 2018 Aug 1;<b>29</b>(8):1853–1860. doi: 10.1093/annonc/mdy218. Stein JE, Soni A, Danilova L, <i>et al</i>. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. <i>Ann Oncol</i>. 2019 Apr 1;<b>30</b>(4):589–596. doi: 10.1093/annonc/mdz019. <h3>Ethics Approval</h3> The study was approved by University of Pittsburgh9s Institutional Review Board, approval number MOD19040237-002. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308399087 created "2022-11-11" @default.
• W4308399087 creator A5000046177 @default.
• W4308399087 creator A5003764313 @default.
• W4308399087 creator A5005266772 @default.
• W4308399087 creator A5006414413 @default.
• W4308399087 creator A5007239425 @default.
• W4308399087 creator A5009423272 @default.
• W4308399087 creator A5009492707 @default.
• W4308399087 creator A5009588391 @default.
• W4308399087 creator A5011411480 @default.
• W4308399087 creator A5013181413 @default.
• W4308399087 creator A5015029502 @default.
• W4308399087 creator A5023763310 @default.
• W4308399087 creator A5024282871 @default.
• W4308399087 creator A5024933766 @default.
• W4308399087 creator A5025286759 @default.
• W4308399087 creator A5026264123 @default.
• W4308399087 creator A5028848169 @default.
• W4308399087 creator A5030169825 @default.
• W4308399087 creator A5033020983 @default.
• W4308399087 creator A5035471137 @default.
• W4308399087 creator A5039812436 @default.
• W4308399087 creator A5058605525 @default.
• W4308399087 creator A5059251810 @default.
• W4308399087 creator A5063337705 @default.
• W4308399087 creator A5063784705 @default.
• W4308399087 creator A5066579768 @default.
• W4308399087 creator A5068025925 @default.
• W4308399087 date "2022-11-01" @default.
• W4308399087 modified "2023-09-30" @default.
• W4308399087 title "605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results" @default.
• W4308399087 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0605" @default.
• W4308399087 hasPublicationYear "2022" @default.
• W4308399087 type Work @default.
• W4308399087 citedByCount "1" @default.
• W4308399087 countsByYear W43083990872023 @default.
• W4308399087 crossrefType "proceedings-article" @default.
• W4308399087 hasAuthorship W4308399087A5000046177 @default.
• W4308399087 hasAuthorship W4308399087A5003764313 @default.
• W4308399087 hasAuthorship W4308399087A5005266772 @default.
• W4308399087 hasAuthorship W4308399087A5006414413 @default.
• W4308399087 hasAuthorship W4308399087A5007239425 @default.
• W4308399087 hasAuthorship W4308399087A5009423272 @default.
• W4308399087 hasAuthorship W4308399087A5009492707 @default.
• W4308399087 hasAuthorship W4308399087A5009588391 @default.
• W4308399087 hasAuthorship W4308399087A5011411480 @default.
• W4308399087 hasAuthorship W4308399087A5013181413 @default.
• W4308399087 hasAuthorship W4308399087A5015029502 @default.
• W4308399087 hasAuthorship W4308399087A5023763310 @default.
• W4308399087 hasAuthorship W4308399087A5024282871 @default.
• W4308399087 hasAuthorship W4308399087A5024933766 @default.
• W4308399087 hasAuthorship W4308399087A5025286759 @default.
• W4308399087 hasAuthorship W4308399087A5026264123 @default.
• W4308399087 hasAuthorship W4308399087A5028848169 @default.
• W4308399087 hasAuthorship W4308399087A5030169825 @default.
• W4308399087 hasAuthorship W4308399087A5033020983 @default.
• W4308399087 hasAuthorship W4308399087A5035471137 @default.
• W4308399087 hasAuthorship W4308399087A5039812436 @default.
• W4308399087 hasAuthorship W4308399087A5058605525 @default.
• W4308399087 hasAuthorship W4308399087A5059251810 @default.
• W4308399087 hasAuthorship W4308399087A5063337705 @default.
• W4308399087 hasAuthorship W4308399087A5063784705 @default.
• W4308399087 hasAuthorship W4308399087A5066579768 @default.
• W4308399087 hasAuthorship W4308399087A5068025925 @default.
• W4308399087 hasBestOaLocation W43083990871 @default.
• W4308399087 hasConcept C121608353 @default.
• W4308399087 hasConcept C126322002 @default.
• W4308399087 hasConcept C143998085 @default.
• W4308399087 hasConcept C167672396 @default.
• W4308399087 hasConcept C203014093 @default.
• W4308399087 hasConcept C203092338 @default.
• W4308399087 hasConcept C2776107976 @default.
• W4308399087 hasConcept C2777701055 @default.
• W4308399087 hasConcept C2778292576 @default.
• W4308399087 hasConcept C2779013556 @default.
• W4308399087 hasConcept C2780030458 @default.
• W4308399087 hasConcept C2780283643 @default.
• W4308399087 hasConcept C31760486 @default.
• W4308399087 hasConcept C530470458 @default.
• W4308399087 hasConcept C535046627 @default.
• W4308399087 hasConcept C61238886 @default.
• W4308399087 hasConcept C71924100 @default.
• W4308399087 hasConcept C8891405 @default.
• W4308399087 hasConcept C90924648 @default.
• W4308399087 hasConceptScore W4308399087C121608353 @default.
• W4308399087 hasConceptScore W4308399087C126322002 @default.
• W4308399087 hasConceptScore W4308399087C143998085 @default.
• W4308399087 hasConceptScore W4308399087C167672396 @default.
• W4308399087 hasConceptScore W4308399087C203014093 @default.
• W4308399087 hasConceptScore W4308399087C203092338 @default.
• W4308399087 hasConceptScore W4308399087C2776107976 @default.
• W4308399087 hasConceptScore W4308399087C2777701055 @default.
• W4308399087 hasConceptScore W4308399087C2778292576 @default.
• W4308399087 hasConceptScore W4308399087C2779013556 @default.
• W4308399087 hasConceptScore W4308399087C2780030458 @default.
• W4308399087 hasConceptScore W4308399087C2780283643 @default.
• W4308399087 hasConceptScore W4308399087C31760486 @default.
• W4308399087 hasConceptScore W4308399087C530470458 @default.
• W4308399087 hasConceptScore W4308399087C535046627 @default.

• next